Never two without three ! After the successive announcements from the American laboratories Pfizer / BioNTech and Moderna, it is the turn of the French pharmaceutical group Sanofi to announce spectacular advances in the manufacture of a vaccine against Covid-19. Last Sunday, Olivier Bogillot, president of Sanofi France, indicated on CNEWS that he would be available from June.
A French vaccine available in June
Olivier Bogillot announced on CNEWS that researchers from the French pharmaceutical group had obtained convincing results during phase II, carried out on several hundred patients. Sanofi has also decided to simultaneously launch the production of doses in December and the phase III tests which should be published in May. The president of Sanofi France specified that the latter would be carried out on “Several tens of thousands of patients”, which will make it possible to better analyze the benefit / risk ratio. However, the laboratory does not yet know whether it will take “one or two doses” for the vaccine to be effective. Another significant advantage of the vaccine that Sanofi is developing against Covid-19, it can be stored in the refrigerator, like that of the flu. Conversely, that of Pfizer / BioNTech requires a temperature of -70 ° C.
Several vaccines in clinical trials
The Covid-19 pandemic has mobilized researchers around the world. For the time being, 48 candidate vaccines are being tested on humans around the world. But only 11 of them have reached phase III, the last stage before the drug’s agencies authorize its marketing. If Pfizer / BioNTech have taken a little lead in this vaccine race, Olivier Bogillot delays by explaining “That a single laboratory will not be able to provide all the doses for the whole planet. We will have to have several winners at the end of this race ”.
